Paper33782830
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
Humeniuk R and 11 others. Clin Pharmacokinet, 2021. Cited by 104 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Papers, record 33782830. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33782830
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenosine Monophosphate | Major topic |
| Alanine | Major topic |
| Antiviral Agents | Major topic |
| COVID-19 Drug Treatment | Major topic |
| Adenosine | |
| Adult | |
| Animals | |
| Area Under Curve | |
| Dose-Response Relationship, Drug | |
| Drug Interactions | |
| Furans | |
| Half-Life | |
| Humans | |
| Metabolic Clearance Rate | |
| Pyrroles | |
| SARS-CoV-2 | |
| Triazines |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32145190 | Liver injury in COVID-19: management and challenges. | Lancet Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32145190 | PubMed |
| 2 | 32598831 | Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32598831 | PubMed |
| 3 | 32340833 | Coronavirus disease 2019 (COVID-19): A literature review. | J Infect Public Health | 2020 | https://conductscience.org/library/papers/32340833 | PubMed |
| 4 | 32649078 | Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32649078 | PubMed |
| 5 | 32574236 | Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19? | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32574236 | PubMed |
| 6 | 32054787 | Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/32054787 | PubMed |
| 7 | 26934220 | Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. | Nature | 2016 | https://conductscience.org/library/papers/26934220 | PubMed |
| 8 | 32668216 | Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. | Cell Rep | 2020 | https://conductscience.org/library/papers/32668216 | PubMed |
| 9 | 33501997 | Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19. | Clin Pharmacol Ther | 2021 | https://conductscience.org/library/papers/33501997 | PubMed |
| 10 | 32884226 | Clinical characteristics and risk factors for liver injury in COVID-19 patients in Wuhan. | World J Gastroenterol | 2020 | https://conductscience.org/library/papers/32884226 | PubMed |
| 11 | 32284326 | Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. | J Biol Chem | 2020 | https://conductscience.org/library/papers/32284326 | PubMed |
| 12 | 32516797 | Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. | Nature | 2020 | https://conductscience.org/library/papers/32516797 | PubMed |
| 13 | 28659436 | Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. | Sci Transl Med | 2017 | https://conductscience.org/library/papers/28659436 | PubMed |
| 14 | 32278175 | COVID-19: A promising cure for the global panic. | Sci Total Environ | 2020 | https://conductscience.org/library/papers/32278175 | PubMed |
| 15 | 32119133 | Inclusion of Adolescents With Adults in Phase 3 Clinical Trials: Overview of the Current State and a Call for Action. | J Clin Pharmacol | 2020 | https://conductscience.org/library/papers/32119133 | PubMed |
| 16 | 28262699 | GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. | Sci Rep | 2017 | https://conductscience.org/library/papers/28262699 | PubMed |
| 17 | 32459919 | Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32459919 | PubMed |
| 18 | 32553666 | COVID-19 and the liver. | J Hepatol | 2020 | https://conductscience.org/library/papers/32553666 | PubMed |
| 19 | 32967965 | Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. | J Biol Chem | 2020 | https://conductscience.org/library/papers/32967965 | PubMed |
| 20 | 20724498 | Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution. | Drug Metab Dispos | 2010 | https://conductscience.org/library/papers/20724498 | PubMed |
Cited by83
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 104 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42316440 | Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants. | Clin Transl Sci | 2026 | https://conductscience.org/library/papers/42316440 | PubMed |
| 42104169 | Pharmacokinetics, Safety, and Tolerability of Obeldesivir in Healthy Japanese and White Participants. | Eur J Drug Metab Pharmacokinet | 2026 | https://conductscience.org/library/papers/42104169 | PubMed |
| 42041372 | Antibiotics and Other Drugs Removal by the CytoSorb® Haemoadsorber: A Systematic Review of Available Evidence. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42041372 | PubMed |
| 41920295 | Prospective Study of Treatment with Ensitrelvir for COVID-19 in Patients Undergoing Hemodialysis (PROTECT-HD). | Infect Dis Ther | 2026 | https://conductscience.org/library/papers/41920295 | PubMed |
| 41769697 | Remdesivir in COVID-19: pros and cons. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41769697 | PubMed |
| 41719342 | Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential. | PLoS One | 2026 | https://conductscience.org/library/papers/41719342 | PubMed |
| 41516274 | Natural Fatty Acids as Dual ACE2-Inflammatory Modulators: Integrated Computational Framework for Pandemic Preparedness. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516274 | PubMed |
| 41458994 | Scoping review about pathogenesis, risk factors, and treatment of venous and arterial thrombosis in coronavirus infection. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/41458994 | PubMed |
| 41353130 | Baseline medication profile and risk of CYP3A4 mediated drug-drug interactions among COVID-19 hospitalized patients in Spain. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/41353130 | PubMed |
| 41239269 | Severe myocardium suppression in two congenital heart disease patients after remdesivir use - a case report. | BMC Pediatr | 2025 | https://conductscience.org/library/papers/41239269 | PubMed |
| 41222450 | Characterization of Drug-Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS-CoV-2, in Healthy Participants. | Clin Transl Sci | 2025 | https://conductscience.org/library/papers/41222450 | PubMed |
| 41031289 | Phylogenetic meta-analysis of persistent SARS-CoV-2 infections in immunocompromised individuals highlights the challenges of robust evolutionary rate estimation caused by low genetic diversity. | Virus Evol | 2025 | https://conductscience.org/library/papers/41031289 | PubMed |
| 40700154 | A Novel HPLC-MS/MS Method for the Intracellular Quantification of the Active Triphosphate Metabolite of Remdesivir: GS-443902. | J Xenobiot | 2025 | https://conductscience.org/library/papers/40700154 | PubMed |
| 40573427 | Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different? | Viruses | 2025 | https://conductscience.org/library/papers/40573427 | PubMed |
| 40514753 | Comparative transcriptome analysis of PBMCs in cats diagnosed with and recovered from FIPV. | Lab Anim Res | 2025 | https://conductscience.org/library/papers/40514753 | PubMed |
| 40261493 | Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19. | Clin Pharmacokinet | 2025 | https://conductscience.org/library/papers/40261493 | PubMed |
| 40196380 | Antivirals in COVID-19: A Focus on Pediatric Cardiac Patients. | Can J Infect Dis Med Microbiol | 2025 | https://conductscience.org/library/papers/40196380 | PubMed |
| 40146185 | Application of Machine Learning and Mechanistic Modeling to Predict Intravenous Pharmacokinetic Profiles in Humans. | J Med Chem | 2025 | https://conductscience.org/library/papers/40146185 | PubMed |
| 39945591 | Pharmacokinetics of SARS-CoV-2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment. | Clin Transl Sci | 2025 | https://conductscience.org/library/papers/39945591 | PubMed |
| 39871315 | Remdesivir-induced severe hypoglycemia in an elderly man without diabetes: a case report. | J Pharm Health Care Sci | 2025 | https://conductscience.org/library/papers/39871315 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33782830
GET https://conductscience.org/api/papers/v1/33782830/references?page=2